MYC and neoplasm: Inhibitors against CDK7 and CDK9 demonstrate potent anti-tumor effects in MYC-driven cancers, including T cell acute lymphoblastic leukemia, mixed-lineage leukemia, neuroblastomas and small cell lung cancers [146].